Heinz Schwer

Chief Executive Officer
Microbiology
ViraTherapeutics
Austria

Business Expert Microbiology
Biography

Dr. Schwer is the Chief Executive Officer of ViraTherapeutics. He served three years as CEO of Lanthio Pharma B.V., a Dutch drug development company that was acquired by MorphoSys AG. He led the company’s effort in advancing its therapeutic program from pre-clinical into clinical stage. He was co-founder and CEO of Sloning Biotechnology, a biotech company that became market leader in generating recombinant gene libraries for pharma and industrial biotech. Dr. Schwer received his PhD in clinical chemistry from University of Regensburg, was a postdoctoral fellow at Harvard Medical School at the Beth Israel Hospital and Dana-Faber Cancer Institute and holds an MBA from Henley Management College, UK.

Research Intrest

 virus-based therapeutics ,anti-cancer therapeutics